PMID- 37701026
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231106
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 14
DP  - 2023
TI  - Inadequate gastric preparation and its associated factors for magnetically 
      controlled capsule endoscopy.
PG  - 1184754
LID - 10.3389/fphar.2023.1184754 [doi]
LID - 1184754
AB  - Goals: To explore factors associated with inadequate gastric preparation for MCE. 
      Background: Factors associated with inadequate gastric preparation for 
      magnetically controlled capsule endoscopy (MCE) remains unclear. Study: Data of 
      patients who underwent MCE from June 2021 to July 2022 were prospectively 
      collected. The gastric cleanliness score (GCS) of the six stomach regions 
      (gastric cardia, fundus, body, angulus, antrum, and pylorus) was recorded. 
      Patients with GCS score >/=18 were defined as the adequate preparation. Factors 
      related to inadequate gastric preparation were analyzed using a logistic 
      regression model with estimated odds ratios (OR). Results: The mean GCS score of 
      211 patients was 17.01 +/- 2.82. In the multivariable analysis, proton pump 
      inhibitor (PPI) use (OR 3.57; 95% CI 1.69-7.95; p < 0.01) and premedication time 
      after administering simethicone <30 min (OR 2.86; 95% CI 1.10-7.39; p = 0.03) 
      were independent risk factors for inadequate gastric preparation. Comparing the 
      gastric cleanliness of different locations, the median GCS of the lower stomach 
      [10.00, IQR (9.50, 11.00)] was significantly higher than that of the upper 
      stomach [7.00, IQR (6.00, 8.00)] (p <0.001). Conclusion: PPI use and inadequate 
      premedication time (<30 min) may reduce the quality of gastric preparation for 
      MCE. The type, dose, duration of medication, and discontinuation time of PPIs was 
      well worth further exploration. Appropriate control of the type and time of 
      premedication may be the key to improving overall gastric cleanliness.
CI  - Copyright (c) 2023 Kong, Peng, Li, Tian, Li, Chen, Zuo and Li.
FAU - Kong, Qing-Zhou
AU  - Kong QZ
AD  - Department of Gastroenterology, Qilu Hospital, Shandong University, Jinan, 
      Shandong, China.
FAU - Peng, Cheng
AU  - Peng C
AD  - Department of Gastroenterology, Qilu Hospital, Shandong University, Jinan, 
      Shandong, China.
FAU - Li, Zhen
AU  - Li Z
AD  - Department of Gastroenterology, Qilu Hospital, Shandong University, Jinan, 
      Shandong, China.
FAU - Tian, Bao-Ling
AU  - Tian BL
AD  - Department of Gastroenterology, Qilu Hospital, Shandong University, Jinan, 
      Shandong, China.
FAU - Li, Yue-Yue
AU  - Li YY
AD  - Department of Gastroenterology, Qilu Hospital, Shandong University, Jinan, 
      Shandong, China.
FAU - Chen, Fei-Xue
AU  - Chen FX
AD  - Department of Gastroenterology, Qilu Hospital, Shandong University, Jinan, 
      Shandong, China.
AD  - Shandong Provincial Clinical Research Center for Digestive Disease, Jinan, 
      Shandong, China.
AD  - Robot Engineering Laboratory for Precise Diagnosis and Therapy of GI Tumor, Qilu 
      Hospital, Shandong University, Jinan, Shandong, China.
FAU - Zuo, Xiu-Li
AU  - Zuo XL
AD  - Department of Gastroenterology, Qilu Hospital, Shandong University, Jinan, 
      Shandong, China.
AD  - Shandong Provincial Clinical Research Center for Digestive Disease, Jinan, 
      Shandong, China.
AD  - Robot Engineering Laboratory for Precise Diagnosis and Therapy of GI Tumor, Qilu 
      Hospital, Shandong University, Jinan, Shandong, China.
FAU - Li, Yan-Qing
AU  - Li YQ
AD  - Department of Gastroenterology, Qilu Hospital, Shandong University, Jinan, 
      Shandong, China.
AD  - Shandong Provincial Clinical Research Center for Digestive Disease, Jinan, 
      Shandong, China.
AD  - Robot Engineering Laboratory for Precise Diagnosis and Therapy of GI Tumor, Qilu 
      Hospital, Shandong University, Jinan, Shandong, China.
LA  - eng
PT  - Journal Article
DEP - 20230828
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC10493275
OTO - NOTNLM
OT  - gastric disease
OT  - magnetically controlled capsule endoscopy
OT  - preparation
OT  - proton pump inhibitor
OT  - simethicone
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/09/13 06:42
MHDA- 2023/09/13 06:43
PMCR- 2023/08/28
CRDT- 2023/09/13 03:59
PHST- 2023/03/12 00:00 [received]
PHST- 2023/08/14 00:00 [accepted]
PHST- 2023/09/13 06:43 [medline]
PHST- 2023/09/13 06:42 [pubmed]
PHST- 2023/09/13 03:59 [entrez]
PHST- 2023/08/28 00:00 [pmc-release]
AID - 1184754 [pii]
AID - 10.3389/fphar.2023.1184754 [doi]
PST - epublish
SO  - Front Pharmacol. 2023 Aug 28;14:1184754. doi: 10.3389/fphar.2023.1184754. 
      eCollection 2023.